Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
28 févr. 2020 07h00 HE
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
02 déc. 2019 10h37 HE
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
14 nov. 2019 07h00 HE
|
Fulcrum Therapeutics
– Announced preliminary results of a Phase 1 clinical trial of losmapimod in FSHD patients – – Initiated IND-enabling studies for FTX-6058 for the potential treatment of sickle cell disease and...
Fulcrum Therapeutics to Present at the Stifel 2019 Healthcare Conference
13 nov. 2019 08h01 HE
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
06 nov. 2019 08h01 HE
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Host Key Opinion Leader Breakfast Symposium on Facioscapulohumeral Dystrophy (FSHD), on November 7, 2019
31 oct. 2019 08h00 HE
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
04 oct. 2019 04h30 HE
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting
01 oct. 2019 07h00 HE
|
Fulcrum Therapeutics
Oral presentation to highlight Phase 1 data on safety, tolerability and target engagement of losmapimod in treatment of FSHDCompany also announces updated preclinical data on FTX-6058 for potential...
Fulcrum Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
03 sept. 2019 16h01 HE
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
26 août 2019 07h00 HE
|
Fulcrum Therapeutics
– Completed initial public offering, raising $72.0 million in gross proceeds – – Initiated ReDUX4, a Phase 2b clinical trial of losmapimod in FSHD – – Initiated a Phase 2 open label clinical trial...